Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cangene has received approval from Health Canada for its HepaGam B hyperimmune product for the treatment of hepatitis B.
Subscribe to our email newsletter
Health Canada has issued a Notice of Compliance with conditions which confers marketing approval to the drug in Canada, while requiring the company to continue with a confirmatory clinical study. The approved indication is for the prevention of hepatitis B recurrence following liver transplantation in adult patients who have low levels or no hepatitis B virus replication.
HepaGam B is the only intravenous product licensed in Canada for this indication. A Notice of Compliance with conditions is granted to provide patients who are suffering from serious, life-threatening or severely debilitating illnesses or conditions, accelerated access to promising new therapies.
HepaGam B was approved last year by the FDA for treatment following acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAG-positive persons and household exposure to persons with acute hepatitis B virus infection.